89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

Pharmaceuticals

Albert J. Chang²  Ravindra DeSilva¹  Sandeep Jain¹  Kimberley Lears²  Buck Rogers² 

[1] Department of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA;Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA;

关键词: HER2;    PET;    ⁸⁹Zr;    immunoPET;   

DOI  :  10.3390/ph5010079

来源: mdpi

【 摘 要 】

The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20–30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile ⁸⁹Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the ⁸⁹Zr-trastuzumab produced by this simpler method.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.